Pipeline of Depression Market Covering Therapeutics Under Development for H2 2016

Complete report on H2 2016 pipeline review of Depression with 158 market data tables and 17 figures, spread across 494 pages is available at http://www.rnrmarketresearch.com/depression-pipeline-review-h2-2016-market-report.html .

Companies discussed in this Depression Pipeline Review, H2 2016 report include AB Science SA, Acetylon Pharmaceuticals, Inc., Ache Laboratorios Farmaceuticos S/A, Adamed Sp. z o.o., Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc., Alkermes Plc, Allergan Plc, Alvogen Korea Co., Ltd., Amorsa Therapeutics Inc., Anavex Life Sciences Corp., Angelini Group, Angita B.V., Araim Pharmaceuticals, Inc., AstraZeneca Plc, Avanir Pharmaceuticals, Inc., Axsome Therapeutics Inc, Azevan Pharmaceuticals, Inc., BioCrea GmbH, Biogen Inc, Biohaven Pharmaceutical Holding Company Limited, BioLite, Inc., Bionomics Limited, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Calico LLC, Celon Pharma Sp. z o.o., Cerecor Inc., Clera Inc., D-Pharm Ltd., Delpor, Inc., e-Therapeutics Plc, Eisai Co., Ltd. , Eli Lilly and Company, Evotec AG, Fabre-Kramer Pharmaceuticals, Inc., GlaxoSmithKline Plc, GliaCure Inc., H. Lundbeck A/S, Heptares Therapeutics Limited, Hua Medicine (Shanghai) Ltd., Hyundai Pharmaceutical Co., Ltd., Impel NeuroPharma, Inc., INSYS Therapeutics, Inc., Intas Pharmaceuticals Ltd., Intra-Cellular Therapies, Inc., INVENT Pharmaceuticals, Inc., Johnson & Johnson, KemPharm, Inc., Lead Discovery Center GmbH, Les Laboratoires Servier SAS, Lixte Biotechnology Holdings, Inc., Luye Pharma Group Ltd., Mapi Pharma Ltd., Mapreg S.A.S., Meta-IQ ApS, Methylation Sciences Inc., miCure Therapeutics Ltd., Mitsubishi Tanabe Pharma Corporation, Navya Biologicals Pvt Ltd, Neuralstem, Inc., Neurocrine Biosciences, Inc., NeuroNascent, Inc., NeurOp, Inc, Newron Pharmaceuticals S.p.A. , Nippon Chemiphar Co., Ltd., nLife Therapeutics, S.L., Novartis AG, Omeros Corporation, Otsuka Holdings Co., Ltd., Pfizer Inc., Pherin Pharmaceuticals, Inc., Polleo Pharma Limited, Protagenic Therapeutics Inc. , Relmada Therapeutics, Inc., Reviva Pharmaceuticals Inc., Richter Gedeon Nyrt., Saniona AB, SK Biopharmaceuticals Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Supernus Pharmaceuticals, Inc., Suven Life Sciences Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Takeda Pharmaceutical Company Limited, Tetra Discovery Partners LLC, Trevena, Inc., TRImaran Pharma, Inc., Turing Pharmaceuticals AG, VistaGen Therapeutics , Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Zogenix, Inc. and Zysis Limited.

Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=725390 .

Depression pipeline therapeutics constitutes close to 177 molecules. Out of which approximately 153 molecules are developed by Companies and remaining by the Universities/Institutes. Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.  The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 25, 25, 1, 67, 16 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 8 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. Driven by data built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Depression and reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Depression therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Depression.

Explore more reports on Neurology therapeutics.

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.

Contact:  
Ritesh Tiwari
2nd floor, Metropole,
Next to Inox theatre, Bund garden road,
Pune-411001
Maharashtra, India.
+1 888 391 5441
[email protected]